ClinicalTrialStartPulse: all 1,000 record reports, page 5 of 5

Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 801 to 1,000: Janssen Research & Development, LLC: Phase 3 study closed enrollment, 20284 enrolled (Atrial Fibrillation) to Yale University: Not applicable (device, behavioral) study in Readmission, Readmission Rates (800 participants). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.

US

• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 20284 enrolled (Atrial Fibrillation)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 2517 enrolled (Prostatic Neoplasms)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 539 enrolled (Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 655 enrolled (Sjogrens Syndrome)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 743 enrolled (Multiple Myeloma)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 813 enrolled (Arthritis, Psoriatic)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 864 enrolled (Multiple Myeloma)
• Janssen Research & Development, LLC: Phase 3 study closed enrollment, 896 enrolled (Colitis, Ulcerative)
• Janssen Research & Development, LLC: Phase 3 study in Prostatic Neoplasms (400 participants)
• Janssen Research & Development, LLC: Phase 4 study closed enrollment, 411 enrolled (Arthritis, Psoriatic)
• Janssen Scientific Affairs, LLC: Observational study closed enrollment, 21190 enrolled (Psoriasis)
• Johns Hopkins Bloomberg School of Public Health: Not applicable (device, behavioral) study in Food Choices (450 participants)
• Johns Hopkins Bloomberg School of Public Health: Not applicable (device, behavioral) study in Food Choices (450 participants)
• Johns Hopkins Bloomberg School of Public Health: Not applicable (device, behavioral) study in Ultra-processed Labels (12400 participants)
• Kailera: Phase 3 study closed enrollment, 1270 enrolled (Obesity With Diabetes, Overweight With Diabetes)
• Kailera: Phase 3 study closed enrollment, 1270 enrolled (Obesity)
• Kailera: Phase 3 study closed enrollment, 2530 enrolled (Obesity, Overweight)
• Kardium Inc.: Observational study started recruiting, 500 planned (Atrial Fibrillation)
• Klein Buendel, Inc.: Not applicable (device, behavioral) study closed enrollment, 1796 enrolled (Cancer)
• Lahey Clinic: Not applicable (device, behavioral) study closed enrollment, 662 enrolled (Lumbar Spondylolisthesis, Grade 1 Spondylolisthesis)
• Lumicell, Inc.: Observational study started recruiting, 1500 planned (Breast Cancer)
• Lumicell, Inc.: Observational study started recruiting, 1500 planned (Hypersensitivity Reactions)
• M.D. Anderson Cancer Center: Early phase 1 study closed enrollment, 630 enrolled (Smoking Cessation)
• M.D. Anderson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 406 enrolled (Advanced Malignant Neoplasm, Caregiver)
• M.D. Anderson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 460 enrolled (Obesity-Related Malignant Neoplasm)
• M.D. Anderson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 479 enrolled (Cancer, Aging)
• M.D. Anderson Cancer Center: Observational study closed enrollment, 450 enrolled (Head and Neck Carcinoma)
• M.D. Anderson Cancer Center: Observational study closed enrollment, 818 enrolled (Colon Adenocarcinoma, Colorectal Carcinoma)
• M.D. Anderson Cancer Center: Observational study in Data Collection, Sickle Cell Disease (500 participants)
• M.D. Anderson Cancer Center: Phase 3 study closed enrollment, 681 enrolled (Breast Cancer)
• MacroGenics: Phase 1 study started recruiting, 314 planned (Urothelial Cancer, GastroEsophageal Cancer)
• Massachusetts General Hospital: Not applicable (device, behavioral) study in Elevated Caregiver Strain, Dementia Caregiver (450 participants)
• Massachusetts General Hospital: Observational study in End Stage Renal Disease (ESRD), Volume Overload (400 participants)
• Mayo Clinic: Not applicable (device, behavioral) study closed enrollment, 680 enrolled (Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm)
• Mayo Clinic: Not applicable (device, behavioral) study in Ostomy (500 participants)
• Medical University of South Carolina: Not applicable (device, behavioral) study closed enrollment, 10469 enrolled (Mental Health Issue, Substance Use Disorders)
• Medtronic Cardiac Ablation Solutions: Observational study closed enrollment, 393 enrolled (Persistent Atrial Fibrillation)
• Medtronic MiniMed, Inc.: Not applicable (device, behavioral) study in Type 1 Diabetes, Type 2 Diabetes (1500 participants)
• Memorial Sloan Kettering Cancer Center: Not applicable (device, behavioral) study closed enrollment, 324 enrolled (Head and Neck Cancer, Head and Neck Tumor)
• Memorial Sloan Kettering Cancer Center: Not applicable (device, behavioral) study closed enrollment, 360 enrolled (Chronic Pain, Musculoskeletal Pain)
• Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 1047 enrolled (Ovarian Cancer, Prostate Cancer)
• Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 338 enrolled (Multiple Ground Glass Opacities (GGOs))
• Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 441 enrolled (Breast Cancer Survivors)
• Memorial Sloan Kettering Cancer Center: Phase 3 study in Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin (14000 participants)
• Memorial Sloan Kettering Cancer Center: Phase 4 study closed enrollment, 807 enrolled (Smoking Cessation)
• Mentor Worldwide, LLC: Not applicable (device, behavioral) study closed enrollment, 3603 enrolled (Primary Breast Augmentation, Primary Breast Reconstruction)
• Mentor Worldwide, LLC: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Breast Reconstruction, Revision Breast Reconstruction)
• Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany: Phase 2 study closed enrollment, 381 enrolled (Systemic Lupus Erythematosus)
• Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 473 enrolled (Gastroesophageal Cancer)
• Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 6033 enrolled (Papillomavirus Infections)
• Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 1104 planned (Diabetic Retinopathy, Macular Edema)
• Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 646 planned (Ovarian Cancer, Peritoneal Cancer)
• Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 802 planned (Ovarian Cancer, Ovarian Neoplasms)
• Mercy BioAnalytics, Inc.: Not applicable (device, behavioral) study in Ovarian Cancer (1750 participants)
• Merz Therapeutics GmbH: Phase 3 study closed enrollment, 808 enrolled (Chronic Migraine)
• Merz Therapeutics GmbH: Phase 3 study closed enrollment, 997 enrolled (Episodic Migraine)
• Miami University: Not applicable (device, behavioral) study in Depression - Major Depressive Disorder, Psychological Distress (330 participants)
• Michigan State University: Not applicable (device, behavioral) study closed enrollment, 935 enrolled (Obesity, Adolescent)
• Milton S. Hershey Medical Center: Not applicable (device, behavioral) study closed enrollment, 702 enrolled (Walking, Difficulty, Mobility Limitation)
• ModernaTX, Inc.: Phase 2 study completed, 1407 enrolled (Norovirus Acute Gastroenteritis)
• Montefiore Medical Center: Not applicable (device, behavioral) study started recruiting, 338 planned (Cesarean Scar Defect)
• Multitude Therapeutics Inc.: Phase 3 study started recruiting, 512 planned (NSCLC (Advanced Non-small Cell Lung Cancer))
• National Cancer Institute (NCI): Observational study closed enrollment, 154900 enrolled (Cancer, Death)
• National Cancer Institute (NCI): Observational study closed enrollment, 500 enrolled (Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis)
• National Cancer Institute (NCI): Phase 2 study closed enrollment, 385 enrolled (Prostate Neoplasms, Prostatic Cancer)
• National Institute of Allergy and Infectious Diseases (NIAID): Observational study in Anosmia, Chronic Obstructive Pulmonary Disease (350 participants)
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): Observational study closed enrollment, 521292 enrolled (Rheumatoid Arthritis, Ankylosing Spondylitis)
• National Institute of Mental Health (NIMH): Observational study in Neuropsychiatric Disorders, Neuroinflammatory Disorders (5000 participants)
• National Institutes of Health Clinical Center (CC): Observational study closed enrollment, 144625 enrolled (Radiology Information Systems)
• National Institutes of Health Clinical Center (CC): Observational study in Blood Donors, Apheresis (5000 participants)
• National Institutes of Health Clinical Center (CC): Observational study started recruiting, 1000 planned (Pulmonary Hypertension)
• National Institutes of Health Clinical Center (CC): Phase 2 study closed enrollment, 622 enrolled (Hemochromatosis)
• Northwestern University: Not applicable (device, behavioral) study closed enrollment, 57589 enrolled (Dementia, Cognitive Impairment)
• Northwestern University: Not applicable (device, behavioral) study in Perinatal Mental Health, Fathers (624 participants)
• Novavax: Phase 4 study terminated, 6500 enrolled (COVID-19, Sars-CoV-2 Infection)
• Novo Nordisk A/S: Phase 3 study closed enrollment, 1205 enrolled (Non-alcoholic Steatohepatitis)
• Novo Nordisk A/S: Phase 3 study in Cardiovascular Risk, Obesity (8500 participants)
• NRG Oncology: Phase 3 study closed enrollment, 475 enrolled (Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma)
• NYU Langone Health: Not applicable (device, behavioral) study closed enrollment, 486 enrolled (Healthy, Family Research)
• NYU Langone Health: Not applicable (device, behavioral) study in Cardiovascular Diseases (1050 participants)
• NYU Langone Health: Phase 2 study in Adenotonsillectomy, Postoperative Pain (500 participants)
• Ohio State University: Observational study in Substance Use Disorder (SUD), Opioid Use Disorder (1200 participants)
• Ohio State University: Phase 2 study in Caregiver Burden, Caregiver Burnout (344 participants)
• Otsuka Pharmaceutical Development & Commercialization, Inc.: Phase 3 study closed enrollment, 538 enrolled (Schizophrenia)
• Otsuka Pharmaceutical Development & Commercialization, Inc.: Phase 3 study started recruiting, 1120 planned (Generalized Anxiety Disorder)
• Ouraring Inc.: Observational study in Trying to Conceive (50000 participants)
• Pacific Institute for Research and Evaluation: Not applicable (device, behavioral) study in Implementation Strategies (1320 participants)
• Pelage Pharmaceuticals, Inc.: Phase 3 study started recruiting, 600 planned (Androgenetic Alopecia)
• Penn State University: Not applicable (device, behavioral) study in COVID-19 Vaccination (1064 participants)
• Pfizer: Observational study closed enrollment, 846279 enrolled (Community-Acquired Pneumonia (CAP))
• Pfizer: Phase 2 study closed enrollment, 507 enrolled (Atopic Dermatitis)
• Pfizer: Phase 2 study closed enrollment, 605 enrolled (Pneumococcal Disease)
• Pfizer: Phase 2 study closed enrollment, 940 enrolled (Overweight, Obesity)
• Pfizer: Phase 3 study closed enrollment, 1035 enrolled (Breast Cancer)
• Pfizer: Phase 3 study closed enrollment, 1078 enrolled (Obesity, Overweight and/or Obesity)
• Pfizer: Phase 3 study closed enrollment, 1571 enrolled (Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo)
• Pfizer: Phase 3 study closed enrollment, 3578 enrolled (Obesity and Overweight)
• Pfizer: Phase 3 study closed enrollment, 609 enrolled (Metastatic Castrate Resistant Prostate Cancer (mCRPC))
• Pfizer: Phase 3 study closed enrollment, 896 enrolled (Ulcerative Colitis)
• Pfizer: Phase 3 study in Asthma (1100 participants)
• Phathom Pharmaceuticals, Inc.: Phase 3 study started recruiting, 500 planned (Symptomatic Non-erosive Gastroesophageal Reflux Disease)
• Philips Digital & Computational Pathology: Observational study in Pathological Processes (470 participants)
• Radnet Management, Inc.: Observational study in Metabolic Dysfunction-steatohepatitis (MASH) (524 participants)
• RAI Services Company: Not applicable (device, behavioral) study in Smoking, Tobacco (480 participants)
• RayzeBio, Inc.: Phase 3 study closed enrollment, 343 enrolled (GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor)
• Reckitt Benckiser Healthcare (UK) Limited: Observational study in Muscle Soreness (600 participants)
• Restor3D: Observational study started recruiting, 2250 planned (Joint Replacement, Arthropathy)
• Rivanna Medical, Inc.: Not applicable (device, behavioral) study in Fracture Arm, Fracture Leg (25000 participants)
• Rochester General Hospital: Observational study closed enrollment, 1320 enrolled (Nasopharyngeal Colonization and Acute Otitis Media)
• Roswell Park Cancer Institute: Not applicable (device, behavioral) study in Cigarette Smoking-Related Carcinoma (600 participants)
• Sagimet Biosciences Inc.: Phase 3 study in Acne Vulgaris (800 participants)
• SalivIQ Diagnostics, Inc.: Observational study in Streptococcal Pharyngitis, Group A Streptococcal Infection (668 participants)
• Sanofi: Observational study completed, 4878935 enrolled (Chlamydial Infections)
• Sanofi: Phase 2 study terminated, 335 enrolled (Asthma)
• Sanofi: Phase 3 study closed enrollment, 1856 enrolled (Dermatitis Atopic)
• Sanofi: Phase 3 study closed enrollment, 464 enrolled (Dermatitis Atopic)
• Sanofi: Phase 4 study in COVID-19 (660 participants)
• Schweitzer Engineering Laboratories: Observational study in Autism Spectrum Disorder (330 participants)
• Shionogi: Phase 3 study started recruiting, 2000 planned (SARS-CoV-2)
• Smith & Nephew, Inc.: Observational study started recruiting, 1000 planned (Knee Injuries, Joint Surface Knee Lesions)
• St. Jude Children's Research Hospital: Not applicable (device, behavioral) study in Stigma (2980 participants)
• Stanford University: Not applicable (device, behavioral) study in Shared Decision-making (600 participants)
• Stanford University: Not applicable (device, behavioral) study started recruiting, 3000 planned (Colorectal Cancer Screening)
• Stanford University: Not applicable (device, behavioral) study started recruiting, 750 planned (Alcohol Misuse)
• SWOG Cancer Research Network: Phase 3 study closed enrollment, 354 enrolled (Colorectal Neoplasms)
• SystImmune Inc.: Phase 1 study in Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors (424 participants)
• SystImmune Inc.: Phase 3 study in Urothelial Cancer, Metastatic Urothelial Cancer (520 participants)
• Takeda: Phase 2 study completed, 324 enrolled (Carcinoma, Non-Small-Cell Lung)
• Takeda: Phase 3 study closed enrollment, 601 enrolled (Psoriatic Arthritis)
• Takeda: Phase 3 study completed, 354 enrolled (Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC))
• Teva Branded Pharmaceutical Products R&D LLC: Phase 2 study closed enrollment, 349 enrolled (Multiple System Atrophy)
• Teva Branded Pharmaceutical Products R&D LLC: Phase 3 study closed enrollment, 2772 enrolled (Asthma)
• Teva Branded Pharmaceutical Products R&D LLC: Phase 3 study closed enrollment, 649 enrolled (Asthma)
• The University of Texas Health Science Center, Houston: Not applicable (device, behavioral) study in Allergic Contact Dermatitis (ACD) (350 participants)
• The University of Texas Health Science Center, Houston: Not applicable (device, behavioral) study started recruiting, 350 planned (Physical Activity)
• TriGemX Bio, Inc.: Phase 3 study started recruiting, 1500 planned (Migraine)
• UNC Lineberger Comprehensive Cancer Center: Not applicable (device, behavioral) study started recruiting, 395 planned (Cancer)
• University College, London: Observational study in Inherited Retinal Degeneration Associated With RPGR Mutations, Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations (4887 participants)
• University of Alabama at Birmingham: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Pregnancy Complications, Maternal Distress)
• University of Alabama at Birmingham: Not applicable (device, behavioral) study started recruiting, 2748 planned (Breast Cancer, Corpus Uteri Cancer)
• University of Arizona: Not applicable (device, behavioral) study completed, 15128 enrolled (Colorectal Cancer)
• University of California, Irvine: Not applicable (device, behavioral) study closed enrollment, 1000 enrolled (Child Development, Brain Development)
• University of California, San Francisco: Not applicable (device, behavioral) study closed enrollment, 1418 enrolled (Colon Cancer, Cancer Colorectal)
• University of California, San Francisco: Not applicable (device, behavioral) study closed enrollment, 353 enrolled (Bladder Cancer, Breast Cancer)
• University of California, San Francisco: Not applicable (device, behavioral) study completed, 456 enrolled (Insomnia, Depression)
• University of California, San Francisco: Not applicable (device, behavioral) study in Inpatient Experience Survey Administration, Inpatient Experience Survey Response (21800 participants)
• University of Chicago: Not applicable (device, behavioral) study started recruiting, 330 planned (Alzheimer s Disease, Dementia)
• University of Cologne: Not applicable (device, behavioral) study in Anxiety and Fear (400 participants)
• University of Illinois Chicago: Not applicable (device, behavioral) study completed, 636 enrolled (Depression)
• University of Kansas Medical Center: Not applicable (device, behavioral) study completed, 410 enrolled (Weight Loss, Pediatric Obesity)
• University of Kansas Medical Center: Not applicable (device, behavioral) study completed, 582 enrolled (Obesity, Obesity, Morbid)
• University of Massachusetts, Worcester: Observational study in Cardiac Arrest, Out-Of-Hospital, Hypotension (1400 participants)
• University of Michigan: Not applicable (device, behavioral) study closed enrollment, 362 enrolled (Alcohol Use Disorder)
• University of Michigan: Not applicable (device, behavioral) study in AI Companionship (1200 participants)
• University of Michigan: Observational study in Traumatic Brain Injury (500 participants)
• University of Nebraska: Observational study in Acute Kidney Injury, Delirium (25000 participants)
• University of New Hampshire: Phase 2 study in Alcohol Misuse Prevention, Sexual Violence Prevention (350 participants)
• University of Pennsylvania: Not applicable (device, behavioral) study closed enrollment, 317 enrolled (Obesity, Childhood)
• University of Pennsylvania: Not applicable (device, behavioral) study completed, 603 enrolled (Psoriasis, Psoriatic Arthritis)
• University of Pennsylvania: Not applicable (device, behavioral) study in Firearm Safety, Firearm Safety Storage (1858 participants)
• University of Pennsylvania: Not applicable (device, behavioral) study in HIV, Hypertension (400 participants)
• University of Pennsylvania: Not applicable (device, behavioral) study started recruiting, 4800 planned (Tobacco Use, Tobacco Use Cessation)
• University of Pennsylvania: Not applicable (device, behavioral) study terminated, 4000 enrolled (Patient Handoff, Healthcare Team)
• University of Pittsburgh: Not applicable (device, behavioral) study closed enrollment, 765 enrolled (Suicide and Depression, Adolescent Behavior)
• University of Rochester: Not applicable (device, behavioral) study closed enrollment, 1175 enrolled (Depression, Insomnia)
• University of South Carolina: Not applicable (device, behavioral) study started recruiting, 350 planned (Doula Support, Postpartum)
• University of Texas at Austin: Not applicable (device, behavioral) study in Alcohol Use, Underage Drinking (440 participants)
• University of Utah: Not applicable (device, behavioral) study in Skin Cancer Prevention, Sun Safety (450 participants)
• University of Utah: Not applicable (device, behavioral) study in Vaccine Confidence, Adolescent Vaccination (2000 participants)
• University of Utah: Phase 3 study closed enrollment, 1455 enrolled (HPV Vaccination, Uptake Vaccination)
• University of Washington: Not applicable (device, behavioral) study completed, 345 enrolled (Alcohol Use, Posttraumatic Stress Disorder)
• University of Wisconsin, Madison: Not applicable (device, behavioral) study completed, 1529 enrolled (Well-Being, Psychological)
• University of Wisconsin, Madison: Not applicable (device, behavioral) study in Myopia, Astigmatism (333 participants)
• University of Wisconsin, Madison: Not applicable (device, behavioral) study started recruiting, 1000 planned (Tick Bites)
• University of Wisconsin, Madison: Not applicable (device, behavioral) study started recruiting, 6900 planned (Diabetic Retinopathy, Diabetes Mellitus)
• University of Wisconsin, Madison: Observational study closed enrollment, 1545 enrolled (Sleep Disorders, Cerebrovascular Disorders)
• VA Office of Research and Development: Not applicable (device, behavioral) study closed enrollment, 368 enrolled (Suicide, Attempted, Suicidal Ideation)
• VA Office of Research and Development: Not applicable (device, behavioral) study in Insomnia Disorder, Mild Traumatic Brain Injury (900 participants)
• VA Office of Research and Development: Not applicable (device, behavioral) study started recruiting, 384 planned (Psychological Distress)
• VA Office of Research and Development: Phase 3 study closed enrollment, 378 enrolled (Prostate Cancer, Oligometastasis)
• VA Office of Research and Development: Phase 3 study started recruiting, 1630 planned (Basal Cell Carcinoma)
• Vanderbilt University Medical Center: Observational study closed enrollment, 377 enrolled (Sickle Cell Disease, Pulmonary Disease)
• Vanderbilt University Medical Center: Observational study completed, 500 enrolled (Microbial Colonization, Eye Diseases)
• Vanderbilt University Medical Center: Phase 4 study started recruiting, 2290 planned (Pain, Post Operative Analgesia)
• Vaxcyte, Inc.: Phase 3 study closed enrollment, 1390 enrolled (Pneumococcal Disease)
• Vaxcyte, Inc.: Phase 3 study completed, 4049 enrolled (Pneumococcal Disease)
• Vertanical GmbH: Phase 3 study started recruiting, 810 planned (Lumbosacral Radiculopathy)
• Viatris Innovation GmbH: Phase 3 study closed enrollment, 451 enrolled (Lupus Erythematosus, Systemic)
• Viatris Innovation GmbH: Phase 3 study closed enrollment, 470 enrolled (Lupus Erythematosus, Systemic)
• Virginia Commonwealth University: Observational study started recruiting, 1000 planned (DM1, Myotonic Dystrophy)
• Wake Forest University Health Sciences: Not applicable (device, behavioral) study started recruiting, 600 planned (Congestive Heart Failure)
• Wake Forest University Health Sciences: Phase 4 study in Hypotension During Surgery, Cesarean Birth (1500 participants)
• Washington State University: Not applicable (device, behavioral) study in Chronic Pain (400 participants)
• Washington University School of Medicine: Not applicable (device, behavioral) study closed enrollment, 600 enrolled (HIV Prevention)
• Washington University School of Medicine: Not applicable (device, behavioral) study in Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder) (10000 participants)
• Washington University School of Medicine: Not applicable (device, behavioral) study in SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder (325 participants)
• Washington University School of Medicine: Not applicable (device, behavioral) study in SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder (325 participants)
• Weill Medical College of Cornell University: Observational study closed enrollment, 1040 enrolled (Stem Cell Transplant Complications, Delirium)
• Yale University: Not applicable (device, behavioral) study in Preventive Medicine, Hypertension (3680 participants)
• Yale University: Not applicable (device, behavioral) study in Readmission, Readmission Rates (800 participants)

Browse ClinicalTrialStartPulse by category and location · Search and filter ClinicalTrialStartPulse